SUSMED,Inc.
Notice Regarding the Start of Sales of Medcle, an App for Insomnia Treatment
Approval for insurance coverage and start of sales for the treatment app Medcle planned to commence in June 2026; sales will be handled in-house; focus on progress of the development pipeline and trends in sales partnerships.
Key Figures
- Sales start timing: June 2026
- Medcle milestone: 200,000,000 yen to be received (to be recognized in the June 2027 term)
- End of sales partnership with Shionogi: August 2026
- Insurance coverage request submitted: Based on information for the fiscal year ending September 2026
AI要約
Section Heading
This IR centers on the sale start of Medcle, a treatment app utilizing Sasmade's DTx platform, and the status of the pipeline, reporting progress on insurance listing and establishment of service provision to medical institutions. It also discusses the growth potential of the DTx market, considerations for insurance reimbursement and reimbursement pricing, and domestic market estimates, clarifying the business viability and competitive landscape of treatment apps.
Section 2 Heading
The document describes the monetization path from the sales start, the progress of the development pipeline (SMD201/105/403, etc.), and the policy and outlook for risks (funding, intellectual property, partner developments).
SUSMED,Inc.
Company overview · Stock price · Financial data · All IR
